Abstract:Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1–42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00167?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00167</a>.Molecular dynamics—8012-9656 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_001.pdb">PDB</a>)Molecular dynamics—S06-1002 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_002.pdb">PDB</a>)Molecular dynamics—S06-1011 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_003.pdb">PDB</a>)Molecular dynamics—S06-1014 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_004.pdb">PDB</a>)Molecular string formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_005.csv">CSV</a>)Compound characterization; inhibitory rates on eeAChE and on eqBChE of partial compounds; molecular docking modes of S06-1002, S06-1011, and S06-1014; molecular dynamic simulation results of S06-1001, S06-1002, S06-1011, and S06-1014; chromatographic and mass spectrometric identification information for S06-1011; standard curves for pharmacokinetics and PAMPA study; quantization of ROS production; protocol for the in vivo experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_006.pdf">PDF</a>)This article has not yet been cited by other publications.

Efficacy and Toxicity Studies In Vitro and in Wild-Type Mice

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Direct Effect of F12511, A Systemic Inhibitor of Acyl-CoA Cholesterol Acyltransferase on Bovine Aortic Endothelial Cells

Inhibiting the cholesterol storage enzyme ACAT1/SOAT1 in aging Apolipoprotein E4 mice alter their brains inflammatory profiles

Myeloid Acat1/Soat1 KO Attenuates Pro-Inflammatory Responses in Macrophages and Protects Against Atherosclerosis in a Model of Advanced Lesions

Inhibiting the Cholesterol Storage Enzyme ACAT1/SOAT1 in Myelin Debris-Treated Microglial Cell Lines Activates the Gene Expression of Cholesterol Efflux Transporter ABCA1

Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation

In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT

Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro , in vivo and in silico studies

Human Acyl-coenzyme A:cholesterol Aacyltransferase(ACAT)

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

In vitro ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer's disease

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate

Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer’s Disease Mouse Model

Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer's disease-like pathology in the APPNL-G-F knock-in mouse model

1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice

In Vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer's Disease.

A Novel Mouse Model of Familial Combined Hyperlipidemia and Atherosclerosis.

HMGCR Inhibitor Restores Mitochondrial Dynamics by Regulating Signaling Cascades in a Rodent Alzheimer's Disease Model

Hepatic Acat2 overexpression promotes systemic cholesterol metabolism and adipose lipid metabolism in mice